| dc.creator |
Anguita, Rodrigo |
|
| dc.creator |
Tasiopoulou, Anastasia |
|
| dc.creator |
Shahid, Syed |
|
| dc.creator |
Roth, Janice |
|
| dc.creator |
Sim, Sing Yue |
|
| dc.creator |
Patel, Praveen J. |
|
| dc.date |
2021-10-01T10:00:03Z |
|
| dc.date |
2021-10-01T10:00:03Z |
|
| dc.date |
2021-06-13 |
|
| dc.date.accessioned |
2023-02-17T19:47:28Z |
|
| dc.date.available |
2023-02-17T19:47:28Z |
|
| dc.identifier |
Anguita, R. et al. (2021a) ‘A Review of Aflibercept Treatment for Macular Disease.’, Ophthalmology and therapy. doi: 10.1007/s40123-021-00354-1. |
|
| dc.identifier |
34120317 |
|
| dc.identifier |
10.1007/s40123-021-00354-1 |
|
| dc.identifier |
https://rde.dspace-express.com/handle/11287/622015 |
|
| dc.identifier |
Ophthalmology and therapy |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/241968 |
|
| dc.description |
Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. In this review, we aim to summarize the scientific evidence and recommendations for use of intravitreal aflibercept in neovascular age-related macular degeneration, diabetic macular oedema, macular oedema associated with retinal vein occlusion, and myopic choroidal neovascularization. |
|
| dc.description |
RD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted. |
|
| dc.description |
Not permitted |
|
| dc.language |
eng |
|
| dc.publisher |
Springer |
|
| dc.relation |
https://dx.doi.org/10.1007/s40123-021-00354-1 |
|
| dc.rights |
© 2021 Springer Nature Switzerland AG. Part of Springer Nature. |
|
| dc.subject |
Aflibercept |
|
| dc.subject |
Diabetic macular oedema |
|
| dc.subject |
Macular oedema associated with vein occlusion |
|
| dc.subject |
Myopic choroidal neovascularization |
|
| dc.subject |
Neovascular age-related macular degeneration |
|
| dc.subject |
VEGF |
|
| dc.title |
A Review of Aflibercept Treatment for Macular Disease |
|
| dc.type |
Journal Article |
|
| dc.type |
Published |
|